Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 17/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2402638 | 0.90 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL2401392 | 0.90 | CRHR1 (0.78) | CRHR1 | |
| SCHEMBL14422134 | 0.89 | CRHR1 (0.80) | CRHR1 | |
| Hydrochloric Acid SCHEMBL2429331 | 0.89 | CRHR1 (0.77) | CRHR1 | |
| SCHEMBL2402897 | 0.89 | CRHR1 (0.85) | CRHR1 | |
| SCHEMBL2401561 | 0.88 | CRHR1 (0.87) | CRHR1 | |
| SCHEMBL2401592 | 0.87 | CRHR1 (0.90) | CRHR1 | |
| SCHEMBL2402557 | 0.87 | CRHR1 (0.81) | CRHR1 | |
| SCHEMBL2402497 | 0.87 | CRHR1 (0.73) | CRHR1 | |
| Hydrochloric Acid SCHEMBL2429610 | 0.86 | CRHR1 (0.89) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1832590-B1 | Heterotricyclic compounds as CRF receptor antagonists | ONO PHARMACEUTICAL CO (JP) | 2011-09-28 | — | — | EP | claimed |
| US-20090137604-A1 | TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | claimed |
| EP-1832590-A2 | Tri- heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-12 | — | — | EP | claimed |
| US-20060122392-A1 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-06-08 | — | — | US | claimed |
| US-20040072833-A1 | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | claimed |
| EP-1354884-A1 | TRICYCLIC AND HETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-22 | — | — | EP | claimed |
| EP-1832590-B1 | Heterotricyclic compounds as CRF receptor antagonists | ONO PHARMACEUTICAL CO (JP) | 2011-09-28 | — | — | EP | disclosed |
| US-7807688-B2 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-7807688-B2 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-7807688-B2 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20090137604-A1 | TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137604-A1 | TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-20090137604-A1 | TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
| US-7459459-B2 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-7459459-B2 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| EP-1832590-A2 | Tri- heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-09-12 | — | — | EP | disclosed |
| US-20060122392-A1 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | ONO PHARMACEUTICAL CO., LTD. | 2006-06-08 | — | — | US | disclosed |
| US-7034153-B2 | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040072833-A1 | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-04-15 | — | — | US | disclosed |
| EP-1354884-A1 | TRICYCLIC AND HETEROCYCLIC DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122392-A1 | Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient | NR3C1, CRHR2, CRHR1 | CRHR1 3/4885 |
| US-20090137604-A1 | TRI-HETEROCYCLIC COMPOUNDS AND A PHARMACEUTICAL COMPRISING THEM AS AN ACTIVE INGREDIENT | NR3C1, CRHR2, CRHR1 | CRHR1 3/4885 |
| US-20040072833-A1 | Tricyclic and heterocyclic derivative compounds and drugs containing these compounds as the active ingredient | CRH, CRHR1, CRHR2 | CRHR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.